The companies will join forces to develop and commercialize ertugliflozin (PF-04971729), an oral sodium glucose cotransporter (SGLT2) inhibitor for type 2 diabetes which is about to begin phase 3 studies.
Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Rasilez, Tekturna) in type 2 diabetics at high risk for cardiovascular and renal events.
To be specific, Merck (MRK) will test a beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor, which the drugmaker notes is the first drug with this type of mechanism to advance to this stage of clinical research.